Clinical trial registry record

Effectiveness of a Joint General Practitioner-Pharmacist Intervention on Benzodiazepine Deprescribing in the Elderly

A registered study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Recruiting.
Evidence
Registered phase not reported study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated June 24, 2026.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT05765656
Last registry update
June 24, 2026
Status
Recruiting
Phase
Phase not reported
Sponsor
Nantes University Hospital
Enrollment
400
Countries
France
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase not reported
Study design
RANDOMIZED · PARALLEL · HEALTH SERVICES RESEARCH · NONE
Evidence population
Human clinical study registration
Participants
400
Population
ALL · 65 Years
Duration
2023-10-16 to 2027-02-16
Intervention
GP - pharmacist collaboration and pharmacist motivational interviewing
Comparator
Usual Care
Outcomes measured
Appropriateness measured by sociological interviews of patients, general practicioners and pharmacists and pharmacists…; Acceptability 1 — 3 months after last inclusion; Acceptability 2 — within 6 months after refusal; Acceptability 3 — 3 months after last inclusion; Cost-Utility analysis assessed following the Haute Autorité de Santé 2020 recommendations — 12 months after the last in…; Fidelity 1 — 12 months after the last inclusion; Fidelity 2 — 12 months after the last inclusion; Fidelity 3 — 6 months after the last inclusion; Fidelity 4 — 6 months after the last inclusion; BZDR consumption — 10 to 12 months after enrollment in the study; Anxiety — 6 and 12 months after enrollment; Insomnia — 6 and 12 months after enrollment; Attachment to BZDR — 6 and 12 months after enrollment; Reported Quality of life of patients — 6 and 12 months after enrollment; Autonomy — 6 and 12 months after enrollment
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase not reportedA trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Deprescribing · 100%Title contains controlled topic terminology. Source terminology contains a controlled topic term. Title supplies ageing or longevity context.

Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.

deprescribing
Read the original source →Export JSON